CN115362175A - 抗acvr1抗体及其用途 - Google Patents

抗acvr1抗体及其用途 Download PDF

Info

Publication number
CN115362175A
CN115362175A CN202180027355.8A CN202180027355A CN115362175A CN 115362175 A CN115362175 A CN 115362175A CN 202180027355 A CN202180027355 A CN 202180027355A CN 115362175 A CN115362175 A CN 115362175A
Authority
CN
China
Prior art keywords
ser
antibody
thr
val
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027355.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·J·艾旦
S·J·哈特塞尔
A·N·伊科诺米迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN115362175A publication Critical patent/CN115362175A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180027355.8A 2020-02-11 2021-02-10 抗acvr1抗体及其用途 Pending CN115362175A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062975047P 2020-02-11 2020-02-11
US62/975,047 2020-02-11
US202063030131P 2020-05-26 2020-05-26
US63/030,131 2020-05-26
PCT/US2021/017427 WO2021163170A1 (en) 2020-02-11 2021-02-10 Anti-acvr1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115362175A true CN115362175A (zh) 2022-11-18

Family

ID=74860418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027355.8A Pending CN115362175A (zh) 2020-02-11 2021-02-10 抗acvr1抗体及其用途

Country Status (11)

Country Link
US (2) US11945872B2 (https=)
EP (1) EP4103617A1 (https=)
JP (1) JP2023519100A (https=)
KR (1) KR20220140802A (https=)
CN (1) CN115362175A (https=)
AU (1) AU2021218675A1 (https=)
CA (1) CA3167441A1 (https=)
IL (1) IL295419A (https=)
MX (1) MX2022009769A (https=)
WO (1) WO2021163170A1 (https=)
ZA (1) ZA202208222B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118955715A (zh) 2018-10-23 2024-11-15 科乐斯疗法公司 Alk2抗体及其使用方法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JP2024532345A (ja) * 2021-09-03 2024-09-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 抗ａｃｖｒ２ａ抗体及びその使用
US20240150474A1 (en) 2022-10-27 2024-05-09 Regeneron Pharmaceuticals, Inc. Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
CA2649770C (en) * 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
US8859752B2 (en) 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JP5642972B2 (ja) 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
BR112017015661A2 (pt) * 2015-01-30 2018-03-20 Saitama Medical University anticorpo anti-alk2
CA3093205A1 (en) 2018-03-05 2019-09-12 Saitama Medical University Pharmaceutical composition for treating or preventing heterotopic ossification
MX2021000977A (es) * 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
CN118955715A (zh) * 2018-10-23 2024-11-15 科乐斯疗法公司 Alk2抗体及其使用方法
US12428484B2 (en) * 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
JP7668013B2 (ja) * 2019-07-26 2025-04-24 学校法人 埼玉医科大学 Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体

Also Published As

Publication number Publication date
WO2021163170A1 (en) 2021-08-19
IL295419A (en) 2022-10-01
KR20220140802A (ko) 2022-10-18
JP2023519100A (ja) 2023-05-10
CA3167441A1 (en) 2021-08-19
US20210253716A1 (en) 2021-08-19
US20240190974A1 (en) 2024-06-13
EP4103617A1 (en) 2022-12-21
ZA202208222B (en) 2023-10-25
US11945872B2 (en) 2024-04-02
AU2021218675A1 (en) 2022-08-18
MX2022009769A (es) 2022-11-09

Similar Documents

Publication Publication Date Title
KR102831970B1 (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US20230340160A1 (en) Bispecific t cell activating antigen binding molecules
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
KR102161460B1 (ko) St2 항원 결합 단백질
CN111954680B (zh) IL2Rβ/共同γ链抗体
DK2519543T3 (en) HETERODIMER BINDING PROTEINS AND USE THEREOF
KR101459159B1 (ko) Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도
KR20210123350A (ko) 항-il2 수용체 감마 항원-결합 단백질
KR20180054837A (ko) 인간 cd40에 특이적으로 결합하는 작용성 항체 및 사용 방법
CN115362175A (zh) 抗acvr1抗体及其用途
TW202539736A (zh) 對胃抑肽受體(gipr)具特異性之抗原結合蛋白之用途
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
KR20150122761A (ko) Ｔ 세포 활성화 항원 결합 분자
TW201217397A (en) Antibodies to MAdCAM
KR20190101435A (ko) 에스. 아우레우스 용혈소 ａ 독소에 대한 인간 항체
KR20220042137A (ko) 항-뉴욕 식도 편평 세포 암종 1 (ny-eso-1) 항원-결합 단백질 및 이의 사용 방법
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20230027300A (ko) Il-10 뮤테인 및 이의 융합 단백질
US20240150474A1 (en) Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification
RU2800649C2 (ru) Моноклональные антитела против рецептор-связывающего домена spike-белка вируса sars-cov-2 и их антигенсвязывающие фрагменты, кодирующие их нуклеиновые кислоты, а также способы применения
RU2838544C1 (ru) МИНИАТЮРНЫЕ АНТИТЕЛОПОДОБНЫЕ БЕЛКИ УПРАВЛЕНИЯ И НАВИГАЦИОННОГО КОНТРОЛЯ (miniGNC) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination